FinDogFinDog
Monday, November 2, 2026Closing data · 4:00 PM ET
English
Log in

DHR

Danaher CorporationNYSE · Life Sciences Tools & Services · Health Care
Previous close
227.97
Change
−4.26 / −1.83%
FinDog View
Bullish
52-Week Range ?
160.93 – 242.80
P/E (TTM) ?
37.7
Sector median 29.9
Forward P/E ?
24.4
Based on consensus earnings for the next 12 months
Market Cap
$163B
1M
+6.50%
S&P 500 −2.28% over same period
Volume / Avg Volume
3.8M / 5.0M
0.75× average · Volume on 10-30
Latest earnings analysisFY2026 Q3Reported 2026-10-21

Danaher Q3 FY2026: adjusted EPS $2.11 beats, guidance raised

Danaher beat on the numbers management controls: adjusted EPS of $2.11 topped the $1.9359 consensus, revenue rose 8.5%, and free cash flow jumped 19.0% to $1.63 billion. The catch is that core growth was only 3.0%, with respiratory testing a 2.5-point headwind and acquisitions and divestitures subtracting 6.5 points. Read this quarter as a margin-and-cash story, not a demand story.

Read the full analysis →
Revenue$6.55BYoY +8.30%
EPS (non-GAAP)$2.11Beatest. $1.94
Next-day move−1.76%

Price History

Closing price · USD1M6M1Y5Y
150175200225250EFY26 Q3 EarningsEFY26 Q2 EarningsEFY26 Q1 EarningsEFY25 Q4 Earnings2025-112026-022026-052026-082026-11

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 38.61M6M1Y5Y
30354045502025-112026-022026-052026-082026-11

Recent Earnings

Click to read the FinDog analysis
PeriodReportedRevenueEPS Actual / Est.Next-Day MoveAnalysis

Next Earnings

Date and consensus from the earnings calendar; the analysis is generated automatically after the releaseEarnings Calendar →
Report date
2027-01-26
in 85 days · After hours
Consensus EPS
$2.61
Last quarter EPS $2.11
Avg. next-day move over the last 7 reports
±2.3%

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data
Valuation
P/E is at percentile 28 of its 5-year rangeCheap
5-year range 29.0 – 48.2 · Median 39.7
Last 4 quarters: $894M in buybacks + $1.0B in dividends, 1.17% of market cap combined
P/E (TTM)
37.7
P/B
3.1
P/S
6.4
Dividend Yield
0.49%
Earnings Reaction
Over the last 7 reports, the stock moved ±2.3% on average on the first trading day after, rising 3 times
Most recent −1.76%
Volatility & Correlation
1-year beta 0.47 · Correlation with S&P 500 0.20Low beta
Annualized volatility 30% vs. 13% for the S&P 500
Insider Trading
View all →
Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 0 · $0.00MSell 3 · $21.5MNet selling $21.5M
  • 10-28McGrew MatthewExecutive Vice PresidentSell$7.0M29,754 shares · 2 trades · Avg price 235.74
  • 10-28Bouda ChristopherVP, Chief Accounting OfficerSell$1.8M7,598 shares · 2 trades · Avg price 234.56
  • 08-21Blair RainerPresident & CEOSell$12.7M58,255 shares · 3 trades · Avg price 218.63
Multi-Quarter Financial Trends
View all quarters →
Last 12 quarters · As reported by the company
QuarterRevenue ($B)YoYGross MarginOperating Income ($B)Net Income ($B)Free Cash Flow ($B)EPS
FY2026 Q36.55+8.3%58.5%1.251.241.631.75
FY2026 Q26.27+5.5%57.6%1.130.871.271.23
FY2026 Q15.95+3.7%60.3%1.341.031.091.45
FY2025 Q46.84+4.6%58.0%1.501.201.751.69
FY2025 Q36.05+4.4%58.2%1.150.911.371.27
FY2025 Q25.94+3.4%59.3%0.760.561.090.77
FY2025 Q15.74−0.9%61.2%1.270.951.051.32
FY2024 Q46.54+2.1%59.5%1.431.091.501.50
FY2024 Q35.80+3.1%58.7%0.960.821.221.12
FY2024 Q25.74−2.9%59.7%1.170.911.131.22
FY2024 Q15.80−2.6%60.2%1.311.091.451.45
FY2023 Q46.41−10.2%—1.34—1.191.45

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →
TickerCompanyMarket CapP/ERevenue YoYGross Margin1MView